Kiniksa Pharmaceuticals Q2 2023 Earnings Report $20.59 +0.10 (+0.49%) (As of 12/20/2024 05:16 PM ET) Earnings HistoryForecast Kiniksa Pharmaceuticals EPS ResultsActual EPS-$0.02Consensus EPS -$0.16Beat/MissBeat by +$0.14One Year Ago EPSN/AKiniksa Pharmaceuticals Revenue ResultsActual Revenue$71.47 millionExpected Revenue$52.33 millionBeat/MissBeat by +$19.14 millionYoY Revenue GrowthN/AKiniksa Pharmaceuticals Announcement DetailsQuarterQ2 2023Date7/25/2023TimeN/AConference Call ResourcesSlide DeckPress ReleaseKNSA Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Kiniksa Pharmaceuticals Earnings HeadlinesKiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx ConferenceNovember 26, 2024 | globenewswire.comIs Kiniksa Pharmaceuticals (KNSA) Top Performing European Stock Heading into 2025?November 13, 2024 | msn.comDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."December 22, 2024 | Banyan Hill Publishing (Ad)Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare ConferenceNovember 12, 2024 | globenewswire.comKiniksa Pharmaceuticals International, plc Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest ForecastsNovember 1, 2024 | finance.yahoo.comKiniksa Pharmaceuticals International, plc (KNSA) Q3 2024 Earnings Call TranscriptNovember 1, 2024 | seekingalpha.comSee More Kiniksa Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kiniksa Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kiniksa Pharmaceuticals and other key companies, straight to your email. Email Address About Kiniksa PharmaceuticalsKiniksa Pharmaceuticals (NASDAQ:KNSA), a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.View Kiniksa Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
